{"id":3333,"date":"2026-09-21T09:00:00","date_gmt":"2026-09-21T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3333"},"modified":"2026-09-21T20:18:23","modified_gmt":"2026-09-22T00:18:23","slug":"epigenetic-silencer-durably-suppresses-hepatitis-b-dna","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3333","title":{"rendered":"Epigenetic Silencer Durably Suppresses Hepatitis B DNA"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

nChroma Bio<\/p>\n

Event Type<\/strong><\/p>\n

Peer-Reviewed Preclinical Publication<\/p>\n

Modality<\/strong><\/p>\n

LNP-Delivered Epigenetic Silencer (Guide RNA and mRNA)<\/p>\n

Asset<\/strong><\/p>\n

CRMA-1001<\/p>\n

Target<\/strong><\/p>\n

Episomal and Integrated Hepatitis B Virus DNA (DNA Methylation, Non-Cutting)<\/p>\n

Disease Area<\/strong><\/p>\n

Chronic Hepatitis B<\/p>\n

Summary<\/h4>\n

A peer-reviewed Nature Biomedical Engineering paper reports CRMA-1001, an LNP-delivered guide RNA and mRNA epigenetic silencer that deposits DNA methylation on episomal and integrated hepatitis B virus DNA without cutting it. A single dose reduced viral biomarkers by more than three log10 in mouse models, while three monthly doses produced undetectable HBsAg and HBV DNA in up to 90% of animals at six months. Translation remains preclinical.<\/p>\n

CRMA-1001 combines a programmable DNA-binding component with DNMT3A and DNMT3L-derived methylation machinery. The guide directs the transient protein to a conserved HBV locus, creating methylation across a local region and repressing viral transcription. The design aims to silence both cccDNA-like episomes and integrated viral DNA, a persistent source of HBsAg that current nucleoside analogues do not eliminate.<\/p>\n

In nonhuman primates, the highest tested dose caused transient liver transaminase elevations. RNA expression and DNA methylation profiling in primary human cells found no detectable unintended human genomic targets under the tested conditions. These assays reduce but do not eliminate off-target risk, and neither mouse model fully recapitulates human chronic infection, immune tolerance, HBV genotype diversity, or authentic cccDNA biology.<\/p>\n

Deep Analysis<\/h4>\n

One interpretation is that programmable methylation may create a finite treatment capable of durable antigen suppression without double-strand breaks. Multi-month persistence after transient exposure and activity against episomal and integrated templates support that model. The countercase is that durable repression in simplified models may not persist in chronically infected human hepatocytes with heterogeneous viral reservoirs and ongoing immune pressure.<\/p>\n

A second interpretation is that avoiding nuclease cleavage reduces genotoxicity compared with DNA cutting. That is directionally plausible, but targeted methylation can still alter nearby transcription, and permanent epigenetic states are difficult to reverse. Bulk profiling may miss rare cell-specific events, long-range chromatin effects, or selection of edited hepatocyte clones. LNP delivery must also achieve sufficient liver coverage without dose-limiting innate immune or hepatotoxic effects.<\/p>\n

Company and Product Background<\/h4>\n

nChroma Bio develops epigenetic medicines. Chronic hepatitis B persists through nuclear covalently closed circular DNA and integrated viral DNA. Current antivirals suppress replication but rarely remove surface antigen. CRMA-1001 is designed to recruit endogenous methylation machinery to viral DNA so transcription remains repressed after the transient editor has cleared.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Mechanism: targeted DNA methylation silences HBV transcription without cutting DNA.<\/li>\n
  • Preclinical efficacy: more than three log10 biomarker reduction, and up to 90% undetectable HBsAg and HBV DNA after three doses in mouse models.<\/li>\n
  • Delivery: guide RNA and effector mRNA co-encapsulated in a hepatocyte-directed LNP.<\/li>\n
  • Safety watch: transient NHP transaminase elevations at the highest dose and unresolved rare off-target methylation.<\/li>\n
  • Upgrade path: genotype breadth, authentic infection models, long-term NHP specificity, scalable CMC, reversible safety controls, and human HBsAg loss with preserved liver function.<\/li>\n
  • Falsifier: failure to reproduce durable suppression in infected human hepatocytes, emergence of escape variants, or clinically relevant off-target methylation.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This is a high-importance platform signal because it combines programmable targeting, non-cutting epigenetic persistence, and systemic LNP delivery against both major HBV DNA reservoirs. Direction remains uncertain: the preclinical evidence is strong enough to justify clinical development, but functional cure language is premature until human antigen loss, viral control, and long-term genomic safety are demonstrated.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal importance is high because it addresses both major persistent HBV DNA reservoirs with a mechanism distinct from nuclease-based editing. Direction is uncertain given the early preclinical stage. Confidence in the underlying facts is high, based on the peer-reviewed article and deposited sequencing data, while confidence in interpretation is moderate-low because the mechanism is preclinical and long-term human specificity, delivery, and reversibility remain unknown.<\/p>\n","protected":false},"excerpt":{"rendered":"

    A peer-reviewed Nature Biomedical Engineering paper reports CRMA-1001, an LNP-delivered guide RNA and mRNA epigenetic silencer that deposits DNA methylation on episomal and integrated hepatitis B virus DNA without cutting it. A single dose…<\/p>\n","protected":false},"author":1,"featured_media":3338,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[740,739,834],"class_list":["post-3333","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities","tag-chronic-hepatitis-b","tag-epigenetic-editing","tag-nchroma-bio"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3333"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3333\/revisions"}],"predecessor-version":[{"id":3351,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3333\/revisions\/3351"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3338"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3333"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3333"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}